All of Akeso's Innovative Drugs Granted Approval in China's Latest NRDL: Highlighting Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Treatments

Akeso's Drug Inclusion in NRDL: Akeso, Inc. announced that all five of its self-developed innovative drugs have been included in China's updated National Reimbursement Drug List (NRDL) for 2025, effective January 1, 2026, enhancing access to treatments for major diseases like cancer and autoimmune disorders.

Breakthroughs in Cancer Treatment: The company's drugs, including ivonescimab and cadonilimab, have shown significant clinical benefits in treating various cancers, with ivonescimab being the first globally to demonstrate superior efficacy over pembrolizumab in a Phase III trial.

Expansion of Indications: Akeso's drugs, such as penpulimab and ebdarokimab, have successfully negotiated inclusion for multiple indications in the NRDL, addressing conditions like nasopharyngeal carcinoma and psoriasis, thereby broadening treatment options for patients.

Commitment to Innovation: Akeso emphasizes its dedication to developing breakthrough therapies and maintaining a patient-centric approach, aiming to provide affordable and effective treatments while expanding its global presence in the biopharmaceutical industry.